What is an FDA Form 483, and how is it different from a warning letter?

What a Form 483 is

FDA's Form 483 FAQ says the form is issued to firm management at the conclusion of an inspection when the investigator has observed conditions that may constitute violations of the FD&C Act. It says the form does not constitute a final agency determination about whether a condition is a violation. FDA encourages a written response with a corrective action plan.

The response window

FDA's March 2026 draft guidance on responding to 483 observations from drug CGMP inspections recommends responding within 15 business days, and says FDA will not ordinarily delay action such as a warning letter to review a later response. It is draft guidance and covers drug CGMP inspections, so it may not apply to every kind of inspection.

How a warning letter differs

• A 483 records observations at the end of an inspection. A warning letter is a separate communication of FDA's position on violations, usually asking for a written response in 15 working days.
• FDA's Regulatory Procedures Manual calls a warning letter informal and advisory and says FDA does not consider it final agency action.
• The manual says promised or ongoing corrective actions, even if noted on a 483, generally do not prevent a warning letter.
• Not every warning letter follows an inspection. The Pinnacle and Wholesale Peptide letters in our index describe FDA website reviews.

What this does not tell you

FDA publishes no single side-by-side comparison, so the contrast above is our reading of its FAQ and manual. A 483 is not a finding that a company broke the law, and a warning letter is not a court ruling.